Compare RGLD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGLD | MRNA |
|---|---|---|
| Founded | 1981 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2B | 19.7B |
| IPO Year | 1995 | 2018 |
| Metric | RGLD | MRNA |
|---|---|---|
| Price | $266.05 | $50.81 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 12 |
| Target Price | ★ $249.60 | $34.27 |
| AVG Volume (30 Days) | 1.1M | ★ 5.3M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | ★ 32.74 | 21.77 |
| EPS | ★ 6.69 | N/A |
| Revenue | $1,030,471,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $93.18 | $8.74 |
| Revenue Next Year | $4.61 | $16.18 |
| P/E Ratio | $39.71 | ★ N/A |
| Revenue Growth | ★ 43.24 | 4.29 |
| 52 Week Low | $150.75 | $22.28 |
| 52 Week High | $306.25 | $59.55 |
| Indicator | RGLD | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 50.91 |
| Support Level | $253.20 | $47.61 |
| Resistance Level | $305.47 | $54.94 |
| Average True Range (ATR) | 8.91 | 2.53 |
| MACD | 4.14 | -0.21 |
| Stochastic Oscillator | 84.18 | 50.66 |
Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.